Hemofarm – Becomes the New Center of STADA Group

By the decision of STADA’s management, Hemofarm has assumed responsibility for the markets of Poland, the Czech Republic and Slovakia, thereby additionally increasing the area of its regional competence which has so far comprised the markets of the South East Europe (BiH, Montenegro, Slovenia, Croatia, Hungary, Romania, Bulgaria, Macedonia and Albania). This promotion is, as assessed by Stada, a result of the good work of Hemofarm after assuming the leading role of the German Group in South East Europe in 2016.

''The new role granted to Hemofarm is a remarkable recognition of Stada for the work and the results we achieved in the previous period. This is also good news for Serbia and the entire region, particularly bearing in mind that it is rarely seen that a company operating in a non-EU member country is entrusted with managing markets within the EU. Our plans are ever more ambitious with these new markets. The investment will be focused on the expansion of capacities, further upgrading of product quality, research and development of medicinal products, and particularly on the work force – around 3,000 diligent, high-quality, educated people currently employed by Hemofarm” said Ronald Seeliger, Chief Executive Officer of Hemofarm and Vice President of STADA Group.

Apart from playing the leading role in production, Hemofarm has also assumed the role of the promoter of sustainable development and responsible operations in the region.